Design and Synthesis of Glycoside Inhibitors of Glioma and Melanoma Growth

Isabel García-Álvarez, Guillermo Corrales, Ernesto Doncel-Pérez,§ Ana Muñoz, Manuel Nieto-Sampedro,*§ and Alfonso Fernández-Mayoralas*
Instituto de Qumica Orgnica General, CSIC, Juan de la Cierva 3, 28006 Madrid, Spain, Hospital Nacional de Parapljicos, SESCAM, 45071 Toledo, Spain, Instituto Cajal, CSIC, Avda. Doctor Arce 37, 28002 Madrid, Spain, and Laboratorios FAES FARMA, SA, Mximo Aguirre 14, Leioa, Vizcaya
J. Med. Chem., 2007, 50 (2), pp 364–373
DOI: 10.1021/jm0611556
Publication Date (Web): December 22, 2006
Copyright © 2007 American Chemical Society

 Instituto de Química Orgánica General, CSIC.

,

 Instituto Cajal, CSIC.

,
§

 Hospital Nacional de Parapléjicos, SESCAM.

,

 Laboratorios FAES FARMA, SA.

,
*

 To whom correspondence should be addressed. A.F.-M.:  phone, 34 91 562 29 00; fax, 34 91 564 48 53; e-mail, mayoralas@iqog.csic.es. M.N.-S.:  phone, 34 91 585 47 20; fax, 34 91 585 47 54; e-mail, mns@cajal.csic.es

Abstract

Abstract Image

An N-acetylglucosaminide derivative with a pentaerythritol substituent at position C-6 was previously synthesized and shown to inhibit neural tumor growth. Now, we report the preparation of a series of new synthetic compounds introducing systematic changes in the nature, polarity, and size of the sugar substituents. The antimitotic activity of the new compounds was tested on cultured rat (C6) and human (U-373) glioma lines and on a human melanoma line (A-375). The antimitotic and antitumoral activity of the new compounds on glioma cell lines increased up to 2 orders of magnitude with respect to the parent compound or was abolished, permitting a detailed structure−function analysis of the new antitumorals. One of the glycosides inhibited melanoma division with an ID50 below the micromolar range.

Tools

History

  • Published In Issue January 25, 2007
  • Received October 5, 2006

Recommend & Share

Related Content

Other ACS content by these authors: